HK Stock Market Move | XUANZHUBIO-B(02575) increase expands to 30%: Palbociclib in the treatment of breast cancer phase III clinical study data announced at ESMO.

XUANZHUBIO-B (02575) further increased in the afternoon, reaching a high of 59.85 Hong Kong dollars during trading, a rise of over 415% from the IPO price of 11.6 Hong Kong dollars. As of the time of writing, it has increased by 29.67%, trading at 59 Hong Kong dollars with a turnover of 183 million Hong Kong dollars. On the news front, Xuanzhu Bio announced that on October 20 in Germany, at the 2025 European Society for Medical Oncology (ESMO) conference, it presented the interim analysis results of the Phase III clinical trial (BRIGHT-3) for the first-line treatment of advanced HR+/HER2- breast cancer with pyrotinib combined with letrozole or anastrozole in the form of a poster. It is reported that the BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted in 58 centers in China, aiming to evaluate the efficacy and safety of pyrotinib combined with letrozole or anastrozole in the first-line treatment of advanced HR+/HER2- breast cancer. Based on the interim data from the BRIGHT-3 study, the China National Medical Products Administration officially accepted the new drug application for pyrotinib combined with aromatase inhibitors (AI) for the treatment of advanced HR+/HER2- breast cancer on May 14.